Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Regranex Clear all
Completed Not applicable Interventional Results available

Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

NCT01305356
View directory record Official record
Conditions
Degenerative Joint Disease, Congenital Deformity, Arthritis, Osteoarthritis, Rheumatoid Arthritis
Interventions
Augment® Injectable Bone Graft, Autologous bone graft
Device · Procedure
Lead sponsor
BioMimetic Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Tucson, Arizona • San Francisco, California • Glenview, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 5, 2026, 5:28 PM EDT
Not listed Not applicable Interventional

TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers

NCT00389636
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
TheraGauze, Regranex
Device · Drug
Lead sponsor
Solsys Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Sep 5, 2026, 5:28 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Immediate Implant Placement Using Volume-Stable Collagen Matrix Combined With rhPDGF-BB

NCT06038695
View directory record Official record
Conditions
Tooth Extraction, Immediate Implant Placement
Interventions
Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB
Device
Lead sponsor
I-Ching Wang
Other
Eligibility
18 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Rh-PDGF vs EMD for Treatment of Intra-bony Defects

NCT05442034
View directory record Official record
Conditions
Intrabony Periodontal Defect
Interventions
growth factors to help in regeneration
Biological
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Not listed Not applicable Interventional

Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers

NCT00446472
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Regranex®, Hydrogel
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Long Beach, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Sep 5, 2026, 5:28 PM EDT
Withdrawn Phase 1 Interventional

Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers

NCT01353937
View directory record Official record
Conditions
Diabetic Ulcer
Interventions
AMD3100 injection + rhPDGF-BB topical
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
35 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction

NCT06634030
View directory record Official record
Conditions
Wound Healing, Surgical Wound
Interventions
RhPDGF-BB, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
22 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Recombinant Human Platelet-derived Growth Factor in Combination With Collagen Matrix

NCT04462237
View directory record Official record
Conditions
Gingival Recession, Platelet Derived Growth Factor
Interventions
Root coverage procedures
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 5, 2026, 5:28 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of a Known Bioactive Agent on the Resolution of Alveolar Socket Preservation

NCT02802436
View directory record Official record
Conditions
Healing of Extraction Socket
Interventions
Extraction with socket graft
Procedure
Lead sponsor
Boston University
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 5, 2026, 5:28 PM EDT
Terminated Phase 2 Interventional Results available

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

NCT02387957
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Fovista®, bevacizumab, ranibizumab, aflibercept
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 5, 2026, 5:28 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences

NCT05576922
View directory record Official record
Conditions
Implant Complication
Interventions
Prosthetic-surgical approach + autogenous graft, Prosthetic-surgical approach + graft substitute
Other
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 5, 2026, 5:28 PM EDT
Not listed Phase 2 Interventional

Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns

NCT00812513
View directory record Official record
Conditions
Burns, Electric Burns
Interventions
R-Pdf/Gbb 0.01% gel
Drug
Lead sponsor
American Scitech International
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 5, 2026, 5:28 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

NCT02214628
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Fovista® (anti-PDGF BB) plus anti-VEGF
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor

NCT04954664
View directory record Official record
Conditions
Dental Implant, Bone Loss
Interventions
Allograft particles hydrated with rhPDGF, Allograft particles hydrated in a conventional way with saline.
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain

NCT01530126
View directory record Official record
Conditions
Periodontitis
Interventions
B-TCP + 0.3 mg/ml rhPDGF-BB in buffer, B-TCP + 1.0 mg/ml rhPDGF-BB in buffer, B-TCP +buffer
Biological
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 5, 2026, 5:28 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis

NCT04964466
View directory record Official record
Conditions
Bone Loss
Interventions
Amount of PDGF-BB in PRF preparation vs. GEM21, Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation, Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes, Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Evaluating an rhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing

NCT06632418
View directory record Official record
Conditions
Anal Fistula, Complex Perianal Fistula
Interventions
RhPDGF-BB
Drug
Lead sponsor
Alexander Hawkins
Other
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

NCT01746420
View directory record Official record
Conditions
Lateral Epicondylitis
Interventions
rhPDGF-BB Injection, Placebo
Drug
Lead sponsor
BioMimetic Therapeutics
Industry
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 5, 2026, 5:28 PM EDT